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2013, accepted Feermeability glycoprotein (P-gp) mediates the export of drugs from cells located in the small intestine, blood-brain
barrier, hepatocytes, and kidney proximal tubule, serving a protective function for the body against foreign
substances. Intestinal absorption, biliary excretion, and urinary excretion of P-gp substrates can therefore be altered
by either the inhibition or induction of P-gp. A wide spectrum of drugs, such as anticancer agents and steroids, are
known P-gp substrates and/or inhibitors, and many cardiovascular drugs have recently been observed to have
clinically relevant interactions as well. We review the interactions among commonly prescribed cardiovascular drugs
that are P-gp substrates and observe interactions involving P-gp that may be relevant to clinical practice.
Cardiovascular drugs with narrow therapeutic indexes (e.g., antiarrhythmic agents, anticoagulant agents) have
demonstrated large increases in concentrations when coadministered with potent P-gp inhibitors, thus increasing
the risk for drug toxicity. Therefore, dose adjustment or use of alternative agents should be considered when strong
P-gp-mediated drug-drug interactions are present. Finally, interactions between novel drugs and known P-gp
inhibitors are now being systematically evaluated during drug development, and recommended guidelines for the
administration of P-gp substrate drugs will be expanded. (J Am Coll Cardiol 2013;61:2495–502) ª 2013 by the
American College of Cardiology FoundationThe availability of a drug at the site of action for pharmaco-
logical effect is characterized by the processes of absorption,
distribution, metabolism, and elimination. Transporters are
membrane proteins that govern the transport of drugs into and
out of cells, affecting both intracellular and systemic drug
concentration and reducing the cell exposure to potential toxins.
The 2 superfamilies of transporters are the adenosine
triphosphate (ATP)–binding cassette and solute carrier
transporters. Solute carrier transporters comprise facilitated
and ion-coupled transporters, whereas ATP-binding cassette
transporters rely on ATP to actively pump substrates across
cell membranes. The best characterized transporter is
permeability glycoprotein (P-gp; also known as ATP-binding
cassette, subfamily B, member 1 or multidrug resistance-1
[MDR1]). Although many other transporters have been
identiﬁed (1), P-gp appears to be the most relevant to
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bruary 26, 2013.P-gp transport system. The x-ray crystallographic structure
for P-gp is depicted in Figure 1, showing ATP binding to
produce conformation changes resulting in the extrusion of
a substrate to the extracellular space (2). The P-gp transporter
is found in the luminal membrane of the small intestine and
blood-brain barrier and in the apical membranes of excretory
cells such as hepatocytes and kidney proximal tubule epithelia
(Fig. 2) (1). Expression on intestinal epithelial cells is
responsible for efﬂux that limits cellular uptake and absorp-
tion into enterocytes, whereas expression on the canalicular
surface of hepatocytes and renal tubular cells enhances the
elimination of drugs into the bile and urine (Fig. 2) (3).
P-gp expression in the blood-brain barrier plays an
important role in limiting the entry of various drugs into the
central nervous system (Fig. 3) (4). Studies ofwild-type andP-
gp-knockout mice have demonstrated a high efﬂux ratio
of central nervous system drug penetration due to P-gp,
supporting its role in limiting the intracranial drug concen-
trations of its substrates (5). Inhibition of the P-gp transporter
may lead to increased drug delivery to the brain (4). P-gp
expression has been observed in myocardium, although
generally at relatively low levels (6), and studies in knockout
mice models have demonstrated no signiﬁcant effect of P-gp
in heart tissue (7).
Molecules that are P-gp substrates and modulators do not
share any obvious structural characteristics, although many are
cationic and hydrophobic (Table 1) (1,8). Drugs can act
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2496as inhibitors (impairing P-gp-
mediated uptake or efﬂux), in-
ducers (enhancing P-gp activity),
or simply substrates (translocating
across membranes via P-gp), but 1
drug also can have overlapping
roles. The mechanism of P-gp
inhibition is thought to involve
modulation of the membrane
transporter by 1 of 4 pathways:
direct inhibition of binding sites
that block the transport of sub-
strates, ATP binding inhibition,ATP hydrolysis, or coupling of ATP hydrolysis to the
translocation of the substrate. P-gp inhibition most com-
monly involves competition for transport with another drug
with lesser P-gp afﬁnity, and in vitro measurement of efﬂux
ratios across cells in cell lines with high P-gp expression (e.g.,
Caco-2, a cell line of human epithelial colorectal adenocar-
cinoma cells) can be used to characterize the afﬁnity of
a molecule for P-gp and its potential for inhibition.
Although interactions of P-gp with anticancer agents have
been known for decades, many drug-drug interactions
involving P-gp have been recently identiﬁed (9). Because
drugs metabolized by cytochrome P450 (CYP) enzymes tend
to also be substrates for P-gp, it has been hypothesized that
enzyme and transporter pairs act as a coordinated absorption
barrier against foreign substances (1). As more drugs are
systematically evaluated with in vitro systems and P-gp-
knockout mice models, drug-drug interactions previouslyeability Glycoprotein
meability glycoprotein (P-gp). (A) Substrate
from outside the cell to the inner leaﬂet and
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Figure 2 Mechanisms of P-gp-Directed Efﬂux
Permeability glycoprotein (P-gp) is found on the apical/luminal membrane of
intestinal epithelial cells (A), the canalicular membrane of human hepatocytes
(B), and the apical/luminal membrane of renal proximal tubule cells (C).ascribed solely to CYP3A have now been identiﬁed as also
involving P-gp. While substrate speciﬁcity for CYP3A and
P-gp tend to overlap, some drugs are not metabolized by
CYP3A, but are affected by P-gp and vice versa. The route of
drug administration may also be relevant; different routes of
administration (intravenous vs. oral) lead to different inter-
actions because the amount of drug that reaches intestinal,
renal, and hepatic P-gp receptors differs. Oral administration
Figure 3 The Localization of P-gp at the Blood Brain Barrier
The blood-brain barrier (BBB) is formed by endothelial cells and sealed together by
tight junctions; the blood–cerebrospinal ﬂuid (CSF) barrier (BCSFB) is formed by
epithelial cells of the choroid plexus. Tight junctions reduce drug transfer between
blood and CSF, limiting the accessibility of the brain to polar drugs, unless they are
transferred by transport systems. Permeability glycoprotein (P-gp) is an efﬂux
transporter at the luminal membranes of the BBB and the BCSFB that removes
drugs from brain interstitial ﬂuid back to blood or into the CSF, thus preventing the
drug from producing central nervous system effects. The clinical consequences of
increased exposure in the brain may therefore be beneﬁcial or harmful, depending
on the drug. Adapted, with permission, from Eyal et al. (4).
Table 1
P-gp Substrates, Inhibitors, and Inducers,
Organized by Drug Class
Anticancer Agents
Cardiac
Agents
Antimicrobial
Agents
Rheumatologic/
Immunosuppressant
Agents
Actinomycin D* See Table 2 Azithromyciny Cyclosporine*yz
Colchicine* Clarithromyciny Dexamethasonez
Daunorubicin* Erythromycin*y Everolimus*
Doxorubicin*z Itraconazoley Methotrexate*
Etoposide* Ivermectin*y Quinine*
Imatinib* Ketoconazoley Tacrolimus*y
Irinotecan* Meﬂoquiney
Lapatinib* Oﬂoxaciny
Mitomycin C* Posaconazole*
Nilotinib* Quinolones*
Paclitaxel* Rifampin*yz
Tariquidary
Taxol*
Topotecan*
Valspodary
Vinblastine*
Vincristine*
Gastrointestinal
Agents
HIV Protease
Inhibitors
Neurologic
Agents Miscellaneous
Cimetidine*y Indinaviry Amitriptyliney Berberine*
Domperidone* Lopinaviry Carbamazepinez Conivaptany
Loperamide* Maraviroc* Chlorpromaziney Elacridary
Omeprazoley Nelﬁnaviry Desipraminey Fexofenadine*
Ondansetron* Ritonaviry Disulﬁramy Grapefruit juicey
Saquinaviry Doxepiny Isoﬂavonesy
Tipranavirz Fluphenaziney Orange juicey
Haloperidoly Progesteroney
Imipraminey Quercetiny
Lidocaine* Saxagliptin*
Phenytoinz St. John’s wortz
Sertraliney Terfenadine*
Varenicliney Testosteroney
Venlafaxinez Tolvaptan*
Troglitazoney
If a drug is a substrate of P-gp and is coadministered with St. John’s wort, St. John’s wort will be
listed in the labeling along with other known inducers as possibly decreasing plasma levels of the
drug (51). *Substrate. yInhibitor (showed >25% increases in areas under the curve for digoxin,
fexofenadine, and talinolol). zInducer (showed >20% decrease in area under the curve for digoxin
or fexofenadine). Adapted, with permission, from Shapiro and Shear (8).
HIV ¼ human immunodeﬁciency virus; P-gp ¼ permeability glycoprotein.
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effects on absorption and elimination.
In addition, genetic polymorphisms of the MDR1 gene
that codes for P-gp and its effects on the pharmacokinetics
of various drugs have recently been elucidated. The ﬁrst re-
ported polymorphism of MDR1 inﬂuencing pharmaco-
therapy was the single-nucleotide polymorphism C3435T in
exon 26, which affects duodenal P-gp transport of oral
digoxin (10). Subsequently, at least 28 single-nucleotide
polymorphisms have been identiﬁed on the MDR1 gene
that affect the pharmacokinetics of a wide variety of drugs.
No recent comprehensive review of the P-gp transporter
system and its substrates and inhibitors relevant to cardio-
vascular medicine has been published. In this report, we
review the interactions among commonly prescribed
cardiovascular drugs that are P-gp substrates and observe the
potential drug-drug interactions involving P-gp that could
be clinically relevant.Role of Permeability Glycoprotein in
Cardiovascular Therapy
The role of P-gp in cardiovascular therapy is of increasing
interest because of the wide use of cardiovascular drugs
that interact with the P-gp transporter combined with the
narrow therapeutic indexes of many commonly prescribed
antiarrhythmic and anticoagulant agents (9). Interestingly,
the structure and function of P-gp resemble those of an ionchannel, and many P-gp inhibitors (e.g., verapamil, quini-
dine) are ion channel blockers (9).
Substrates, Inducers, and Inhibitors of
Cardiovascular Drugs
Antiarrhythmic drugs. The interaction of digoxin,
a substrate of both intestinal and renal P-gp, with drugs that
inhibit P-gp can lead to toxic accumulations of this cardiac
glycoside, whereas P-gp inducers lower plasma digoxin
concentration (11) (Table 2). Digoxin is not metabolized by
CYP3A but does have a weak afﬁnity for P-gp, thus making it
a useful “probe” substrate drug to investigate potential P-gp
inhibitors (12). In the ﬁrst characterized drug-drug interaction
involving the P-gp transport system, induction of intestinal
Table 2
Cardiovascular Substrates (), Inhibitors (þ), and
Strong Inhibitors (þþ) of Permeability Glycoprotein
Drug Substrate Inhibitor
Antiarrhythmic agents
Amiodarone þþ
Bepridil 
Dronedarone þþ
Digoxin 
Felodipine þ
Propafenone þ
Quinidine  þþ
Verapamil  þþ
Anticoagulant agents
Apixaban 
Dabigatran 
Rivaroxaban 
Edoxaban 
Warfarin  þ
Antihypertensive agents
Aliskiren 
Captopril þ
Carvedilol þþ
Celiprolol 
Diltiazem  þ
Felodipine þ
Isradipine þ
Labetalol 
Losartan  þ
Mibefradil þ
Nadolol 
Nicardipine þþ
Nifedipine þ
Propranolol  þ
Reserpine þ
Talinolol  þ
Telmisartan þ
Timolol 
Antiplatelet agents
Aspirin*
Clopidogrel 
Dipyridamole þ
Prasugrely
Ticagrelor  þ
Statins
Atorvastatin  þþ
Lovastatin 
Other
Avasimibe*
Ranolazine þ
Ambrisentan 
Relative potency was determined from review of studies of both in vitro and clinical pharma-
cokinetics. *Preliminary studies suggest that aspirin and avasimibe may induce permeability
glycoprotein expression, leading to reduced absorption of clopidogrel and digoxin, respectively
(44,52). yNo known interaction
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orally administered digoxin, thereby reducing plasma digoxin
levels (13). Given the narrow therapeutic window of digoxin
(i.e., a 25% increasemay result in toxicity), coadministration of
P-gp inhibitors is of even greater clinical concern.
The most extensively researched cardiovascular drug-drug
interaction involving the P-gp system is that between
digoxin and quinidine. Since the interaction was initially
recognized in 1978, research 2 decades later in both mouse
models and P-gp-expressing cell lines established that quin-
idine increased plasma digoxin concentration by reducing
P-gp-mediated efﬂux of digoxin into the gut and kidneys,
resulting in greater absorption and decreased elimination of
digoxin (14).
Amiodarone, a potent inhibitor of P-gp, increased mean
serum digoxin levels from 0.97 to 1.98 mg/l when admin-
istered orally at doses of 600 to 1,600 mg/day (15). Oral
amiodarone inhibits intestinal P-gp membrane efﬂux of
digoxin and its secretion from renal tubules (15). Because
there is no signiﬁcant change in digoxin pharmacokinetics
after the administration of intravenous digoxin, the most
relevant mechanism of interaction between these 2 drugs
appears to be inhibition of intestinal and renal P-gp-medi-
ated efﬂux of digoxin (16). Thus, when amiodarone is given
to a patient taking oral digoxin, the dose of digoxin should
be reduced by half and plasma levels closely monitored (17).
Dronedarone displays even greater P-gp inhibition than
amiodarone, inhibiting digoxin clearance mediated by P-gp
and increasing steady-state levels up to 2.5-fold (18). In the
Permanent Atrial Fibrillation Outcome Study Using Dro-
nedarone onTopof StandardTherapy study, it was speculated
that digoxin toxicity induced by dronedarone might have
played a role in the increased cardiovascular mortality in the
study group (19). Similar to amiodarone, it is important to
reduce the dose of oral digoxin when dronedarone is coad-
ministered and tomeasure plasma digoxin concentration (18).
Propafenone also increases steady-state serum digoxin
concentrations, although the mechanism involves primarily
decreasing digoxin clearance by the kidneys, rather than
affecting absorption (20). Sotalol neither inhibits nor acts as a
substrate of P-gp (21).
Oral anticoagulants. WARFARIN. Preliminary evidence
suggests that warfarin may inhibit P-gp activity in hepato-
cytes, thus acting as a P-gp substrate and inhibitor in the liver
(22). However, because warfarin is well absorbed from the
intestine with >90% bioavailability, it is unlikely that intes-
tinal P-gp signiﬁcantly affects the absorption of warfarin (23).
DABIGATRAN. Dabigatran, an oral direct thrombin inhib-
itor, acts as a substrate of P-gp. The concomitant admin-
istration with strong P-gp inducers (e.g., rifampin) should
be avoided because the exposure to dabigatran is reduced
(maximal concentration and area under the curve reduced by
66% and 67%, respectively), thus placing patients at risk for
thrombosis (24,25).P-gp inhibition and impaired renal function are 2 major
independent factors that can increase dabigatran concentrations,
with greater effects if both are present. Exposure to dabi-
gatran increased with coadministration of the strong P-gp
inhibitors ketoconazole (by up to 153%), dronedarone (by
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53% to 56%), verapamil, and clarithromycin in phase I
studies (25,26). A reduced dose of dabigatran (75 mg twice
daily) is recommended when combined with dronedarone or
ketoconazole in patients with moderate renal impairment
(estimated creatinine clearance [CrCl] 30 to 50 ml/min).
Dabigatran should not be used in patients with severe renal
impairment (CrCl 15 to 30 ml/min) if a P-gp inhibitor is
being administered or in patients with end-stage renal failure
(CrCl <15 ml/min), regardless of cotherapies (24,25). Stag-
gering the administration of P-gp inhibitors by 2 to 4 h after the
administration of dabigatran could reduce the potential effect of
increased exposure.
In a case report of an elderly patient taking concomitant
dabigatran (75mg twice daily) and amiodarone (200mg/day),
a major bleeding event led to hemorrhagic shock and
subsequent death. The investigators reported a very high
(25-fold) blood level of dabigatran (trough plasma concen-
tration of dabigatran 5,600 ng/ml; expected range: 31 to
225 ng/ml) that might have been due in part to the inhibition
of P-gp by amiodarone, in addition to other factors such as
decreased renal function (27).
In contrast, drug interaction studies with the P-gp
substrates atorvastatin, digoxin, and clarithromycin did not
result in any pharmacokinetic changes of either dabigatran
or the coadministered drugs (24,25,28). Given the relatively
narrow therapeutic index of oral anticoagulant drugs, unless
dedicated pharmacokinetic studies demonstrate otherwise,
dabigatran (and other novel oral anticoagulant drugs) should
be used with caution in the presence of strong P-gp inhib-
itors and inducers (26).
RIVAROXABAN. Rivaroxaban, an oral, direct factor Xa
inhibitor, acts as a substrate of P-gp. In an investigation of
bidirectional efﬂux of the drug across Caco-2, wild-type, and
P-gp-overexpressing cells, rivaroxaban was shown to be
a substrate for, but not an inhibitor of, P-gp (29). These
ﬁndings were conﬁrmed using several known strong P-gp
inhibitors, including ketoconazole and ritonavir, which
inhibited P-gp-mediated efﬂux of rivaroxaban and reduced
drug efﬂux to 45% and 76% of control values, respectively
(29). As with dabigatran, the concomitant administration of
rivaroxaban with strong P-gp inducers (e.g., rifampin) should
be avoided because the exposure to rivaroxaban is reduced,
thus placing patients at risk for thrombosis. Caution should
additionally be exercised with the use of rivaroxaban in
patients with renal impairment (CrCl<50 ml/min) and with
drugs that are strong CYP3A4 inhibitors (30).
APIXABAN. Another oral factor Xa inhibitor, apixaban, has
completed phase III studies in atrial ﬁbrillation, venous
thromboembolism, and acute coronary syndromes, and has
recently been approved for use in stroke prevention in atrial
ﬁbrillation by the U.S. Food and Drug Administration (FDA)
(31). Prescribing information for apixaban became available in
December 2012.Apixaban is a substrate forP-gp.Concomitant
administration of strong P-gp inhibitors (e.g., ketoconazole,itraconazole, ritonavir, or clarithromycin) increases exposure to
apixaban, thus increasing the risk for bleeding. The FDA
recommends decreasing the dose of apixaban to 2.5 mg twice
daily when administered with strong P-gp inhibitors and
recommends avoiding coadministration of apixaban and strong
P-gp inhibitors in patients already on the reduced dose of
apixaban (32). Conversely, the concomitant administration of
strong P-gp inducers (e.g., rifampin, St. John’s wort) decreases
the exposure to apixaban, thus increasing the risk for stroke.The
FDA recommends avoiding the coadministration of apixaban
and strong P-gp inducers (32).
EDOXABAN. Pharmacokinetic and pharmacodynamic studies
were conducted with the orally administered direct factor Xa
inhibitor edoxaban and several cardiovascular drugs known to
be P-gp substrates and/or inhibitors (33). Edoxaban expo-
sure, prothrombin time, and activated partial thromboplastin
time were increased signiﬁcantly after coadministration of
quinidine, verapamil, and dronedarone (33). Atorvastatin
had no effect, whereas amiodarone had an intermediate
effect (33). No clinically signiﬁcant pharmacokinetic or
pharmacodynamic changes were observed with concomitant
administration of edoxaban and digoxin (33).
In light of these data, the ENGAGE AF–TIMI 48
(Effective Anticoagulation With Factor Xa Next Generation
in Atrial Fibrillation–Thrombolysis In Myocardial Infarc-
tion 48) trial mandated a dose reduction of edoxaban by 50%
for patients receiving concomitant cardiovascular medica-
tions that are strong P-gp inhibitors (34). Additionally,
noncardiac medications that are strong P-gp inhibitors were
prohibited (34).
Atrioventricular nodal blocking agents. CALCIUM-CHANNEL
BLOCKERS. In studies using Caco-2 cells, verapamil inhibited
P-gp-mediated digoxin transport, contributing to increased
digoxin concentration (35). The interaction is thought to occur
at the apical membranes in renal tubular cells by blocking P-gp,
which extrudes digoxin out of the cells; verapamil thus
substantially decreases the renal clearance of digoxin (36).
Clinical studies have demonstrated that verapamil administered
as 240 mg/day increased digoxin concentrations by 60% to
80% (36). Verapamil and diltiazem both are substrates for P-gp
(37). Because verapamil, as a P-gp inhibitor, coadministered
with digoxin results in signiﬁcantly increased digoxin concen-
trations, the prescribing information recommends reducing the
dose of digoxin when starting verapamil.
In a study of the effects of several calcium-channel blockers
on the transport of digoxin by P-gp, the inhibitory effects,
in order, were nicardipine > verapamil > diltiazem >
nifedipine (38). These data suggest that calcium-channel
blockers, as a class, should be used cautiously when coad-
ministered with P-gp substrates.
BETA-BLOCKERS. Although the interaction between P-gp
and beta-blockade is limited to in vitro data, its inﬂuence on
digoxin suggests that the clinical relevance may prove
signiﬁcant. Carvedilol inhibits P-gp activity to a similar
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2500degree as verapamil, increasing serum digoxin levels up to
32% (39). Signiﬁcant P-gp inhibition was similarly observed
for bisoprolol and propranolol, whereas atenolol (39),
metoprolol (21), and sotalol (21) had no effect.
STATINS. Several statins, particularly atorvastatin and lova-
statin, have been shown to interact with P-gp as both
substrates and inhibitors at the molecular level (40). Ator-
vastatin inhibits P-gp-mediated digoxin secretion by 58%
(similar to the inhibition observed with verapamil); thus, the
FDA recommends monitoring digoxin levels in patients
taking both medications (41).
Antiplatelet agents. CLOPIDOGREL. Clopidogrel is a sub-
strate for P-gp. Inhibition of P-gp activity by different
modulators increased the absorptive clopidogrel ﬂux by a
maximum of 5- to 9-fold (p < 0.001) over baseline,
increasing intracellular accumulation from 0.99 0.11 pmol/
mg protein by up to 2.5-fold (p < 0.001) (42). Subjects with
genetic variants in ATP-binding cassette, subfamily B,
member 1 (e.g., MDR1) that may lead to increased expres-
sion of P-gp have reduced absorption of clopidogrel and a
corresponding decrease in exposure to active drug metabolite
of clopidogrel produced by CYP2C9 and carboxyesterase
(42). The relative importance of this mechanism involving
MDR1 polymorphisms compared with other well-described
genetic variants (e.g., CYP2C19 alleles) continues to be
evaluated (43).
ASPIRIN. The role of aspirin in the P-gp–mediated transport
of drugs, especially clopidogrel, remains controversial. Caco-2
cell models suggest that aspirin may reduce intestinal
absorption of clopidogrel via P-gp induction (44). However,
in the CURRENT–OASIS 7 (Clopidogrel and Aspirin
Optimal Dose Usage to Reduce Recurrent Events–Seventh
Organization to Assess Strategies in Ischemic Syndromes)
trial comparing double-dose versus standard-dose clopidogrel
and high-dose (300 to 325 mg) versus low-dose (75 to
100 mg) daily aspirin in 25,086 patients with acute coronary
syndromes, there was no signiﬁcant difference in the rate of
cardiovascular death, reinfarction, or recurrent ischemia
through 30 days with clopidogrel (at either dose) related to
the aspirin dose (45). These ﬁndings from CURRENT–
OASIS 7 do not preclude an important pharmacokinetic
interaction, because the study duration was only 30 days (45).
DIPYRIDAMOLE. In vitro studies have shown that dipyridamole
inhibits P-gp (46). Dipyridamole increased digoxin plasma
concentration after a single dose of digoxin by 20% after 4 h of
administration in a randomized, crossover, placebo-controlled
study (47). This modest increase in digoxin level is not likely
to result in a clinically signiﬁcant effect in most patients.
TICLOPIDINE. Results regarding the thienopyridine anti-
platelet agent ticlopidine and P-gp–mediated transport have
been inconclusive. Studies suggest that ticlopidine may
enhance the oral bioavailability of carvedilol, either by
inhibiting CYP or P-gp-mediated efﬂux (48).PRASUGREL. The third-generation thienopyridine prasugrel
is not known to act as a substrate or inhibitor of P-gp,
despite its structural similarity to clopidogrel (41).
TICAGRELOR. Ticagrelor, a reversible P2Y12 inhibitor, app-
ears to act as a substrate of P-gp and may have moderate
inhibitory activity as well. Initial studies have not established
whether the drug passes directly into the bile from the liver
or is transported by intestinal P-gp and secreted from the
systemic circulation into the intestine (49). However, tica-
grelor appears to moderately inhibit P-gp-mediated digoxin
transport in a dose-dependent manner (50). Thus, we
believe it is prudent to monitor plasma digoxin levels when
ticagrelor is coadministered.
Whether different doses of aspirin affect the P-gp transport
of ticagrelor is unclear. Interestingly, in the PLATO
(Platelet Inhibition and Patient Outcomes) study of 18,624
patients hospitalized with acute coronary syndromes, a
statistically signiﬁcant effect modiﬁcation of the relative
beneﬁt of ticagrelor versus clopidogrel was observed, depen-
dent on the dose of aspirin selected by the investigators.
Because aspirin can inhibit P-gp transport and ticagrelor acts
as a P-gp substrate, the ﬁndings of PLATO are intriguing.
However, since higher dose aspirin was used mostly in the
United States, it is also possible that the apparent interaction
between aspirin dose and ticagrelor was confounded by other
factors associated with care in the United States or was due to
chance.
Food and Drug Administration Guidance for
New Drug Development
In 2012, the FDA released guidance on drug-drug inter-
actions to ensure that pharmaceutical companies charac-
terize the effects of the P-gp transporter on new drugs. In
this recent update, the FDA strengthened this recommen-
dation, mandating that “all investigational drugs should be
evaluated in vitro to determine whether they are a potential
substrate of P-glycoprotein” (51). Using in vitro assays,
decision-tree models have become the standard method to
determine whether a drug is a substrate or inhibitor of P-gp
and when a subsequent in vivo clinical study is needed
(Fig. 4) (1).
Clinical Implications
Many cardiovascular drugs, particularly novel anticoagulant
and antiplatelet therapies, act as substrates and inhibitors of
P-gp, leading to clinically signiﬁcant drug-drug interactions
that may play a role in the increased risk for bleeding that
has been reported with these agents (27). Because the use of
multiple concomitant cardiovascular drugs is the rule rather
than the exception, clinicians must be aware when coad-
ministering medications with P-gp substrate or inhibitory
properties. Clinicians should consider dose adjustment or
alternative treatments when drugs with strong P-gp inter-
actions and narrow therapeutic indexes are combined.
Figure 4 Determining if a Drug Is a P-gp Substrate or Inhibitor
A bidirectional transport assay, using a polarized epithelial monolayer that over-
expresses permeability glycoprotein (P-gp), is the accepted method for identifying
P-gp substrates and inhibitors (51). (A) In such an assay, if the ratio of measured
efﬂux to uptake (net ﬂux) of a drug is 2, it is possible that the drug is a P-gp
substrate. This is conﬁrmed with a second assay with same monolayer system and
the addition of a known P-gp inhibitor, such as ketoconazole. If increasing concen-
trations of the P-gp inhibitor lead to decreases in the net ﬂux of the drug, the drug is
likely a P-gp substrate. (B) In the reverse scenario, if the net ﬂux of a known P-gp
substrate, such as digoxin, is decreased by the addition of the drug in question, the
drug is likely a P-gp inhibitor. (C) In this bidirectional transport assay, net ﬂux reﬂects
the difference in movement of drug from apical (A) to basal (B) versus B to A
compartments. For a P-gp substrate, net ﬂux from B to A is2. In the presence of a
P-gp inhibitor, net ﬂux is 0, reﬂecting equal rates of permeation fromA toB andB to A.
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2501Further research is necessary to completely characterize the
extent of these interactions with the P-gp transport system
in clinical pharmacokinetic studies, particularly for newer
antithrombotic and antiarrhythmic agents. Additionally, the
intracranial expression of P-gp has not been well studied.
Whether the P-gp transport system plays an important role
in the risk for intracranial hemorrhage via the modulation
of cerebral concentrations of novel anticoagulant agents
deserves further consideration.
Take-Home Messages
1. Important interactions between commonly used
cardiovascular drugs and a wide variety of medications
are mediated by the P-gp transporter.
2. Cardiovascular drugs with narrow therapeutic indexes
(e.g., antiarrhythmic agents, anticoagulant agents) can
have large increases in concentrations when coad-
ministered with potent P-gp inhibitors, thus increasing
the risk for drug toxicity.
3. Dose adjustment or use of alternative agents should be
considered when strong P-gp-mediated drug-drug
interactions are present.
4. Interactions between novel drugs and known P-gp
inhibitors are now being systematically evaluated
during drug development, and recommended guide-
lines for the administration of P-gp substrate drugs
will be expanded.
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